Scandinavian ChemoTech AB (publ) publishes Interim report Q1 2026

Net sales rose to 2,798 KSEK from 2,472 KSEK, while loss after financial items narrowed to -1,573 KSEK from -3,322 KSEK and EPS improved to -0.06 SEK from -0.14 SEK. Operating cash flow was still negative at -1,143 KSEK, but all orders were delivered by period-end. The main operational update was a clinical study on TSE in equine sarcoid management scheduled for presentation at the upcoming ECVS.

Analysis

This looks less like a revenue inflection and more like a quality-of-earnings cleanup: the company is moving closer to breakeven, but the operating cash burn still says the business is not yet self-funding. That matters because small-cap healthcare names with modest top lines often rerate on perceived momentum, but the market usually gives back most of the pop when working capital or one-off delivery timing normalizes in the next quarter or two.

The more important near-term catalyst is the clinical presentation, not the quarter itself. In this part of the market, conference visibility can create a short-lived information asymmetry: if the data suggest a credible path to vet adoption, the stock can rerate before any meaningful revenue contribution, because investors underwrite optionality on future licensing or repeat orders rather than current sales. The flip side is that event risk is binary—if the presentation is incremental rather than differentiated, the stock can fade quickly once the conference cycle passes.

The second-order risk is channel credibility. Deliveries being complete removes one near-term operational overhang, but it also means the next leg needs either new order flow or a stronger proof point from the study to avoid a gap in momentum. If the study fails to broaden the addressable use case beyond the current niche, competitors with more established veterinary distribution could absorb the attention without needing to directly outperform on efficacy.

My read is that the market will likely overestimate the permanence of a modest earnings improvement and underestimate how much of the setup depends on one upcoming presentation. That creates a classic event-driven asymmetry: decent upside into the conference, but limited fundamental support unless the company can convert scientific credibility into repeat commercial demand over the next 1-2 quarters.

Key Decisions for Investors

• Go tactically long TSE into the ECVS presentation with a 2-6 week horizon; size small and treat it as event optionality, not a fundamentals conviction trade.
• Use call spreads rather than stock for the catalyst: buy near-dated TSE calls and finance with higher-strike calls to cap premium burn if the presentation disappoints.
• If TSE spikes into the conference on anticipation, trim into strength; the risk/reward skews poorer after the event because the stock needs follow-through orders, not just scientific validation.
• For longer-only portfolios, wait for post-conference confirmation of order flow or a second quarter of improved cash generation before adding size; otherwise the cash burn keeps the downside open.
• If liquid enough, pair a modest long TSE event trade against a basket of profitable healthcare small caps to isolate catalyst alpha and reduce market-beta leakage.